Velicept Therapeutics announced that solabegron met the primary endpoint in the phase 2b VEL-2002 study that evaluated patients with overactive bladder (OAB).
Solabegron, a potent and selective beta-3 adrenoreceptor agonist, was evaluated in the 12-week placebo-controlled study (N=435) of women aged 18 to 80 years with OAB. The data showed a statistically significant improvement in the mean change in number or micturitions per day with twice-daily solabegron vs placebo at week 12 (primary endpoint).
Treatment with solabegron also led to statistically significant percent reductions of urge urinary incontinence episodes, dry rate, and urgency episodes. In the study, solabegron was generally well-tolerated with comparable rates of treatment-emergent adverse events between the solabegron and placebo groups.
“We are encouraged by these positive top-line results for VEL-2002 as they are consistent with what we’ve seen in a prior study with solabegron undertaken by GSK and further validate the potential for best-in-class efficacy and improved safety for patients with OAB,” said James Walker, President and Chief Executive Officer, Velicept Therapeutics.
A novel once-daily formulation of solabegron is currently being evaluated in the phase 2b VEL-2001 study. Top-line data will be announced in the 2nd quarter of 2019.
For more information visit Velicept.com.
This article originally appeared on MPR